Literature DB >> 34347347

MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.

Jonathan M Tsai1, Aaron N Hata2, Jochen K Lennerz3.   

Abstract

Comprehensive genetic profiling using next-generation sequencing technologies has become an integral part of precision oncology. Variant annotation requires translating the DNA findings into protein level predictions. In this article we highlight inconsistencies in variant annotation for the MET D1228N exon 19 resistance mutations. MET D1228N and D1246N represent the same resistance mutation in MET exon 14 skipping alterations annotated on different transcripts. Additional examples of relevant variants annotated on different transcripts emphasize the importance of avoiding erroneous interpretation when realizing precision oncology.
© 2021 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34347347      PMCID: PMC8649016          DOI: 10.1002/onco.13924

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  18 in total

1.  Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.

Authors:  M Miller; K Ginalski; B Lesyng; N Nakaigawa; L Schmidt; B Zbar
Journal:  Proteins       Date:  2001-07-01

2.  Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.

Authors:  Hua-Jie Dong; Peng Li; Chang-Ling Wu; Xiao-Yue Zhou; Hong-Jun Lu; Tong Zhou
Journal:  Lung Cancer       Date:  2016-11-09       Impact factor: 5.705

3.  A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.

Authors:  Ralph Tiedt; Elisa Degenkolbe; Pascal Furet; Brent A Appleton; Sabrina Wagner; Joseph Schoepfer; Emily Buck; David A Ruddy; John E Monahan; Michael D Jones; Jutta Blank; Dorothea Haasen; Peter Drueckes; Markus Wartmann; Clive McCarthy; William R Sellers; Francesco Hofmann
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

4.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

Authors:  Rebecca S Heist; Lecia V Sequist; Darrell Borger; Justin F Gainor; Ronald S Arellano; Long P Le; Dora Dias-Santagata; Jeffrey W Clark; Jeffrey A Engelman; Alice T Shaw; A John Iafrate
Journal:  J Thorac Oncol       Date:  2016-06-22       Impact factor: 15.609

Review 5.  The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

Authors:  Hui K Gan; Anna N Cvrljevic; Terrance G Johns
Journal:  FEBS J       Date:  2013-07-08       Impact factor: 5.542

6.  Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity.

Authors:  Claudia Miranda; Giuseppe Zanotti; Sonia Pagliardini; Carola Ponzetto; Marco A Pierotti; Angela Greco
Journal:  Oncogene       Date:  2002-11-28       Impact factor: 9.867

7.  MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Authors:  Rebecca S Heist; Hyo Sup Shim; Shalini Gingipally; Mari Mino-Kenudson; Long Le; Justin F Gainor; Zongli Zheng; Martin Aryee; Junfeng Xia; Peilin Jia; Hailing Jin; Zhongming Zhao; William Pao; Jeffrey A Engelman; A John Iafrate
Journal:  Oncologist       Date:  2016-03-28

8.  Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Authors:  Lars D Engstrom; Ruth Aranda; Matthew Lee; Elizabeth A Tovar; Curt J Essenburg; Zachary Madaj; Harrah Chiang; David Briere; Jill Hallin; Pedro P Lopez-Casas; Natalia Baños; Camino Menendez; Manuel Hidalgo; Vanessa Tassell; Richard Chao; Darya I Chudova; Richard B Lanman; Peter Olson; Lyudmilla Bazhenova; Sandip Pravin Patel; Carrie Graveel; Mizuki Nishino; Geoffrey I Shapiro; Nir Peled; Mark M Awad; Pasi A Jänne; James G Christensen
Journal:  Clin Cancer Res       Date:  2017-08-01       Impact factor: 12.531

9.  Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.

Authors:  M A Pruis; W R R Geurts-Giele; Thüsen J H von der; I C Meijssen; W N M Dinjens; J G J V Aerts; A M C Dingemans; M P Lolkema; M S Paats; H J Dubbink
Journal:  Lung Cancer       Date:  2019-11-18       Impact factor: 5.705

10.  Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.

Authors:  Yu Wang; Zheng Chen; Xiao Han; Jiamei Li; Honglin Guo; Junping Shi
Journal:  Oncologist       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.